When Vanda Pharmaceuticals Inc. released Phase III data showing that insomnia drug tasimelteon (VEC-162) met its primary endpoint of improving short-term sleep onset, the company's stock popped in early trading only to fall more than 15 percent for the day. (BioWorld Financial Watch) Read More